


Adding another important tool in the fight against Covid-19

May 27, 2020



Siemens Healthineers plays a vital role across the COVID-19 patient pathway







Providing quality testing for COVID-19 patients



Antibody testing at scale

Healthing	pM			1 * -1"	
COV	2T	12	DV2T Pak [×]	o depends one if it is the second of the sec	
Viso . Real/Pack		1.11 1.11	**		
				1	

Supporting COVID-19 patients



Molecular SARS-CoV-2 Assay test kit

- CE-marked, FDA EUA approved, WHO EUL
- 100% positive agreement & 100% negative agreement¹
- Planned ramp up to 2.5' tests/month
- Complements and simultaneous with FTD Respiratory Pathogens 21² that identifies 21 different upper respiratory pathogens

Total Antibody Assay: IgG & IgM

- CE-marked, shipping worldwide
- High quality: 99,8% specificity, 100% sensitivity
- High throughput: Up to 440 tests/hour³
- Fast turn around time of 10 min³
- Available on 5 platforms spanning 20K systems worldwide, including largest IB in U.S.
- Production capacity of over 50' tests/month

Providing critical lab tests COVID-19 patients

- Inflammation tests for escalated immune responses (IL-6)
- Coagulopathy tests (D-dimer)
- Tests to aid in managing high-risk patients

Blood Gas Monitoring

- New FDA-cleared RAPIDPoint 500e
- 5x scale of epoc[®] system for near-patient tests

1. In method comparison studies, FTD SARS-CoV-2 has shown Positive Percent Agreement: 100% (91.8-100, 95% CI) and Negative Percent Agreement: 100% (88.7-100, 95% CI) when tested in Copan eSwab nasopharyngeal and oropharyngeal swabs. 2. CE Marked in the EU and RUO in U.S.

3. For Atellica® Solution. Dependent on analyzer configuration and test mix. Product availability varies by country and is subject to local regulatory requirements..


Not all antibody tests are created equal

High quality, extensive reach and targeting the right protein are all essential to ensure we effectively manage the threat of COVID-19



The SARS-CoV-2 Total Assay¹ is a highly sensitive and accurate antibody test

A total antibody test enables a clearer clinical picture over longer period of time.




What is sensitivity and specificity?

A highly sensitive test should capture nearly all true positive results. A highly specific test should avoid nearly all false positive results.









Delivering long-term value as we look toward immunity and vaccination


The test detects antibodies to a key protein on the surface of the virus – a **spike protein**, which binds the virus to cells via a distinct human receptor (ACE2) found in lungs, heart, and multiple organs.

Studies indicate that certain (neutralizing) antibodies to the spike protein can **disarm SARS-CoV-2**, presumably by interfering with the ability of the virus to bind, penetrate and infect human cells.

Reaching millions of patients

~20,000

analyzers worldwide⁴ with the largest installed base in the U.S.



50M/month

Production according to market demand as pandemic evolves

 This test has not been reviewed by the FDA. In the U.S., use of this test is limited to laboratories that are certified under Clinical Laboratory Improvement Amendments of 1988 (CLIA) to perform high-complexity testing. Product availability may vary by country and is subject to regulatory requirements.

3. Based on results for the ADVIA Centaur COV2T assay.

4. Installed base of ADVIA Centaur XP, ADVIA Centaur XPT, ADVIA Centaur CP, Atellica Solution, Dimension Vista and Dimension EXL analyzers

 Dependent on text mix and configuration using Atellica Solution. HOOD05162003093528

2. For samples collected ≥14 days after positive CR results.

SARS-CoV-2 RT PCR detection test developed in record time



Detection

Dual targeting

Evaluates two targets in one test tube, detecting two genes with less test preparation

2-3 hours

Sample-to-answer time, including extraction and result generation



Compatible with equipment widely used in laboratories worldwide



Supply chain expansion to produce **2.5M tests/mo.** dependent on demand

Å

Å

To make larger **Societal impact**



100% Positive agreement, negative agreement¹

In method comparison studies, FTD SARS-CoV-2 has shown Positive Percent Agreement: 100% (91.8-100, 95% CI) and Negative Percent Agreement: 100% (88.7-100, 95% CI) when tested in Copan eSwab nasopharyngeal and oropharyngeal swabs.

2. Depending on the molecular system and lab resources employed.

Innovation and breadth of testing for COVID-19 patients

SIEMENS ... Healthineers








White cell

High risk patients with pre-existing conditions

nine Neutro

Albumin

lě



1) AdvaMedDX, "A Policy Primer on Diagnostics," June 2011.

Diagnosis

© Siemens Healthineers AG, 2020 | 6

SIEMENS Healthineers